Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ahmed Elagamy
Observed names:
A Elagamy,
A. Elagamy,
Elagamy, Ahmed
Institution:
Egyptian Government
Observed institution:
Egyptian Government
ORCID:
0000-0003-0317-800X
Observed ORCID:
0000-0003-0317-800X
OpenAlex ID:
A5020485352
Institutionalizing health technology assessment in Egypt: Situational analysis and roadmap
2022
·
Pilar Pinilla-Dominguez
, Shorouk Taha
, et al.
·
Frontiers in Pharmacology
·
14
PDF
Maximizing the benefits of using biosimilars in Egypt
2023
·
Ahmad Nader Fasseeh
, Baher Elezbawy
, et al.
·
Journal of Pharmaceutical Policy and Practice
·
10
PDF
National Recommendations for Pharmacoeconomic Evaluations Reporting for Reimbursement and Procurement of New Pharmaceutical Applications in Egypt
2024
·
Mary Gamal
, Amal Samir Sedrak
, et al.
·
Global Journal on Quality and Safety in Healthcare
·
6
HPR180 Eligibility of Orphan Drugs for Preferential Reimbursement in Egypt
2022
·
AN Fasseeh
, B Elezbawy
, et al.
·
Value in Health
·
4
Developing a Multicriteria Decision Analysis Framework to Establish Differential Cost-Effectiveness Thresholds for Orphan Drugs in Egypt
2026
·
Ahmad Nader Fasseeh
, Baher Elezbawy
, et al.
·
Bulletin of Faculty of Pharmacy Cairo University
PDF
HTA341 Egyptian Guidelines for Pharmacoeconomic Evaluations: Toward Standardization of Drug Reimbursement Applications
2023
·
M. Roushdy
, G. Elsisi
, et al.
·
Value in Health
PDF
Show more works
View as search
Works count:
9
Citation count:
34
H-index:
4
I10-index:
2
Year
Topic
Type
